Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation.

ABSTRACT:

Importance

The first US Food and Drug Administration-approved interchangeable biosimilar designation-that for insulin glargine-occurred in 2021, enabling pharmacy substitution for the branded originator. However, the impacts of this interchangeable designation on prescription dispensing are unknown.

Objective

To assess impacts of the transition of Semglee to interchangeable designation on prescription dispensing.

Design and setting

This economic evaluation analyzed changes in insulin glargine dispensing before and after the introduction of the interchangeable designation using data collected from IQVIA's National Prescription Audit, a nationally representative comprehensive database of pharmacy dispensing for the US, and PayerTrak. Data cover the time period from Sept

SUBMITTER: Murphy SJ 

PROVIDER: S-EPMC12048848 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature